Age (HR 2.440, 95% CI 1.994–2.984, P < 0.001), Ann Arbor Stage (HR 1.551, 95% CI 1.252–1.923, P < 0.001), pathologic type (HR 2.138, 95% CI 1.435–3.187, P < 0.001), B symptoms(HR 1.444, 95% CI 0.969–2.152, P = 0.071), chemotherapy (HR 0.778, 95% CI 0.623–0.971, P = 0.026), targeted therapy (HR 0.756, 95% CI 0.612–0.936, P = 0.010), LDH (HR 1.639, 95% CI 1.365–1.967, P < 0.001), β2-microglobulin (HR 1.577, 95% CI 1.298–1.917, P < 0.001), and CRP (HR 2.196, 95% CI 1.807–2.669, P < 0.001) were independent predictors for OS in patients with lymphoma (Table 1). The gene discussed is HLA-G; the disease is lymphoma.